AU2015310909B2 - Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine - Google Patents

Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine Download PDF

Info

Publication number
AU2015310909B2
AU2015310909B2 AU2015310909A AU2015310909A AU2015310909B2 AU 2015310909 B2 AU2015310909 B2 AU 2015310909B2 AU 2015310909 A AU2015310909 A AU 2015310909A AU 2015310909 A AU2015310909 A AU 2015310909A AU 2015310909 B2 AU2015310909 B2 AU 2015310909B2
Authority
AU
Australia
Prior art keywords
mva
leu
thr
seq
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015310909A
Other languages
English (en)
Other versions
AU2015310909A1 (en
Inventor
Ulrike DIRMEIER
Jurgen Hausmann
Hubertus Hochrein
Henning Lauterbach
Robin Steigerwald
Ariane Volkmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of AU2015310909A1 publication Critical patent/AU2015310909A1/en
Application granted granted Critical
Publication of AU2015310909B2 publication Critical patent/AU2015310909B2/en
Priority to AU2021209228A priority Critical patent/AU2021209228A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2015310909A 2014-09-03 2015-09-03 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine Active AU2015310909B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021209228A AU2021209228A1 (en) 2014-09-03 2021-07-28 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462045538P 2014-09-03 2014-09-03
US62/045,538 2014-09-03
US201462055154P 2014-09-25 2014-09-25
US62/055,154 2014-09-25
PCT/EP2015/070161 WO2016034678A2 (en) 2014-09-03 2015-09-03 Recombinant modified vaccinia virus ankara (mva) filovirus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021209228A Division AU2021209228A1 (en) 2014-09-03 2021-07-28 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine

Publications (2)

Publication Number Publication Date
AU2015310909A1 AU2015310909A1 (en) 2017-03-02
AU2015310909B2 true AU2015310909B2 (en) 2021-05-27

Family

ID=54145734

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015310909A Active AU2015310909B2 (en) 2014-09-03 2015-09-03 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine
AU2021209228A Abandoned AU2021209228A1 (en) 2014-09-03 2021-07-28 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021209228A Abandoned AU2021209228A1 (en) 2014-09-03 2021-07-28 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine

Country Status (14)

Country Link
US (2) US10576141B2 (enExample)
EP (1) EP3188752A2 (enExample)
JP (2) JP6823586B2 (enExample)
KR (2) KR102812180B1 (enExample)
CN (2) CN112972668A (enExample)
AU (2) AU2015310909B2 (enExample)
CA (1) CA2959105C (enExample)
IL (2) IL250552B (enExample)
MX (1) MX2017002791A (enExample)
MY (1) MY193417A (enExample)
SG (2) SG11201701506PA (enExample)
UA (1) UA126848C2 (enExample)
WO (1) WO2016034678A2 (enExample)
ZA (1) ZA201701077B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
JP6325751B2 (ja) 2014-11-04 2018-05-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１６ワクチン
WO2016083472A1 (en) * 2014-11-26 2016-06-02 Neuravi Limited A clot retrieval device for removing occlusive clot from a blood vessel
WO2016115116A1 (en) * 2015-01-12 2016-07-21 Geovax, Inc. Compositions and methods for generating an immune response to a hemorrhagic fever virus
US10639366B2 (en) * 2015-02-25 2020-05-05 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
ES2944314T3 (es) 2016-01-08 2023-06-20 Geovax Inc Composiciones y procedimientos para generar una respuesta inmunitaria frente a un antígeno asociado a un tumor
US20190030157A1 (en) 2016-02-03 2019-01-31 Geovax Inc. Compositions and Methods for Generating an Immune Response to a Flavivirus
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
US11078282B2 (en) 2016-04-15 2021-08-03 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
US10517944B2 (en) * 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
EP3529361B1 (en) * 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CN110662758A (zh) 2017-03-16 2020-01-07 高山免疫科学股份有限公司 Cd80变体免疫调节蛋白及其用途
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
CA3061678A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
US20200171141A1 (en) * 2017-07-18 2020-06-04 Geovax, Inc. Compositions and Methods for Generating an Immune Response to LASV
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
GB201716181D0 (en) * 2017-10-04 2017-11-15 Univ Cape Town Recombinant mva with modified hiv-1 env
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
PT3697810T (pt) 2017-10-18 2026-02-19 Alpine Immune Sciences Inc Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
CN121499810A (zh) * 2018-09-28 2026-02-10 剑桥企业有限公司 疫苗和方法
EP3887394A2 (en) 2018-11-30 2021-10-06 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
KR20220154114A (ko) 2020-02-14 2022-11-21 지오박스, 인크. 백신 및 SARS-CoV2에 대한 면역 반응을 유도하기 위한 그의 용도
BR112022017438A2 (pt) 2020-03-12 2022-10-18 Bavarian Nordic As Composições que melhoram a estabilidade do poxvírus
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN115819616B (zh) * 2021-07-28 2025-04-11 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
WO2024188801A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Use of quail cell lines for poxvirus production
AU2024234386A1 (en) 2023-03-10 2025-08-28 Bavarian Nordic A/S Production of poxviruses from quail cell cultures
WO2024188802A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures
CN120795167A (zh) * 2025-04-15 2025-10-17 佰芮慷(广州)细胞医药科技有限公司 一种靶向人eb病毒的嵌合抗原受体car、car-nk细胞及用途
CN120843742A (zh) * 2025-09-09 2025-10-28 军事科学院军事医学研究院军事兽医研究所 一种泛哺乳动物丝状病毒检测用引物组及其检测试剂盒和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586331B1 (en) * 2001-10-01 2008-05-28 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Development of a preventive vaccine for filovirus infection in primates
CA2776391C (en) * 2001-10-01 2015-03-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
JP5046941B2 (ja) * 2004-09-27 2012-10-10 アメリカ合衆国 エボラ及び他のウイルスに対する防御に最適化されたワクチン
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
US20120251502A1 (en) * 2008-10-24 2012-10-04 The Government of the US as Represented by the Secretary of the Dept. of health Human Ebola Virus Species and Compositions and Methods Thereof
AU2009317517B2 (en) * 2008-11-21 2014-12-04 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
US9097713B2 (en) * 2009-09-02 2015-08-04 The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus
TR201902214T4 (tr) * 2010-04-16 2019-03-21 Glaxosmithkline Biologicals Sa Şempanze adenoviral vektörü-bazlı filovirüs aşıları.
IN2014DN09351A (enExample) * 2012-04-12 2015-07-17 Univ Pennsylvania
GB201303406D0 (en) 2013-02-26 2013-04-10 Health Prot Agency Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HENNING LAUTERBACH ET AL, "Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity", FRONTIERS IN IMMUNOLOGY, (2013-01-01), vol. 4, doi:10.3389/fimmu.2013.00251, ISSN 1664-3224 *
HODGE J W ET AL, VACCINE, vol. 27, no. 33, (2009), pages 4475 - 4482 *
HUTCHINGS, CL ET AL, "Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge", INFECTION AND IMMUNITY, (2007), vol. 75, no. 12, pages 5819 - 5826 *
K. L. WARFIELD ET AL, "Advances in Virus-Like Particle Vaccines for Filoviruses", JOURNAL OF INFECTIOUS DISEASES (2011), vol. 20432-46, 90, 91, 92-100, no. suppl 3, pages S1053 - S1059 *
KEEFER, MC ET AL, "A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects", VACCINE, vol. 29, no. 10, (2010), pages 1948 - 1958 *
RIMMELZWAAN G F ET AL, "Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara", EXPERT REVIEW OF VACCINES, FUTURE DRUGS (2009), vol. 8, no. 4, pages 447 - 454 *
SOPRANA, E. ET AL, "Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene", JOURNAL OF VIROLOGICAL METHODS, vol. 174, no. 1, (2011), pages 22 - 28 *

Also Published As

Publication number Publication date
CN106999565B (zh) 2021-03-05
KR102812180B1 (ko) 2025-05-23
CA2959105C (en) 2023-10-17
WO2016034678A2 (en) 2016-03-10
JP6823586B2 (ja) 2021-02-03
WO2016034678A3 (en) 2016-06-02
CN112972668A (zh) 2021-06-18
ZA201701077B (en) 2022-07-27
CN106999565A (zh) 2017-08-01
JP7113924B2 (ja) 2022-08-05
MY193417A (en) 2022-10-12
US11338030B2 (en) 2022-05-24
KR20170048396A (ko) 2017-05-08
KR102736868B1 (ko) 2024-12-02
CA2959105A1 (en) 2016-03-10
UA126848C2 (uk) 2023-02-15
US20170304427A1 (en) 2017-10-26
EP3188752A2 (en) 2017-07-12
KR20230134155A (ko) 2023-09-20
MX2017002791A (es) 2017-05-30
SG10201901735XA (en) 2019-03-28
SG11201701506PA (en) 2017-03-30
JP2021063112A (ja) 2021-04-22
AU2015310909A1 (en) 2017-03-02
IL290052A (en) 2022-03-01
US20200268872A1 (en) 2020-08-27
BR112017003908A2 (pt) 2018-02-27
IL250552B (en) 2022-02-01
NZ729012A (en) 2023-12-22
JP2017527557A (ja) 2017-09-21
AU2021209228A1 (en) 2021-08-19
US10576141B2 (en) 2020-03-03
IL250552A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
AU2015310909B2 (en) Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine
US11571471B2 (en) Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine
CA2879915C (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
US20250387463A1 (en) Recombinant Modified saRNA (VRP) and Vaccinia Virus Ankara (MVA) Prime-Boost Regimen
EA039715B1 (ru) Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
BR112017003908B1 (pt) Vacina contra filovírus de vírus de vaccinia modificado recombinante ankara (mva)
CA3009928C (en) Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
HK1205459B (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)